retatrutide triple hormone receptor agonist metabolic obesity mechanism of action Substack Series 3 6: – The Next Frontier in Longevity and Health Retatrutide dose: the complete guide – Retatrutide | GLP-1R/GIPR/GCGR ligand |

The FDA label for Zepbound does not list hormonal interaction as a mechanism

Unlike traditional weight loss drugs that mainly suppress appetite, retatrutide targets several pathways simultaneously

Practical strategies to minimise gastrointestinal discomfort include eating smaller, lower-fat meals, avoiding alcohol, staying well hydrated, and injecting at a consistent time each week

(Source: In August 2025 , Viking Therapeutic announced encouraging mid-stage trial results for its experimental oral/injectable weight loss drug VK2735, which achieved up to 12.2% body weight reduction over 12 weeks, through shares dropped due to higher treatment discontinuation from gastrointestinal side effects

They can't compete with prescription treatments

[1] [2] Additionally, they have been associated with acute pancreatitis in some cases